Cours suspendu

Communiqués Lumos Pharma, Inc.

Actions

LUMO

US55028X1090

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/12/2024			Varia. 5j.	Varia. 1 janv.
4,340 ^USD	-.--%		-.--%	-

12/12/24	Double Point Ventures LLC a finalisé l'acquisition de Lumos Pharma, Inc. (NasdaqGM:LUMO)	CI
21/11/24	Lumos Pharma, Inc. annonce la mise à jour des données de phase 2 d'OraGrowtH présentées à l'ESPE 2024	CI

Communiqués

12/12/24	Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma	GL
25/11/24	Lumos Pharma : Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM 201 to 24 Months in PGHD and Correlation of Growth to LUM 201’s Unique Pulsatile Mechanism of Action Form 8 K	PU
21/11/24	Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action	AQ
21/11/24	Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action	GL
08/11/24	Lumos: Q3 Earnings Snapshot	AQ
30/10/24	Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024	GL
23/10/24	Lumos Pharma : Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) Form 8 K	PU
23/10/24	Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)	AQ
23/10/24	Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)	GL
25/09/24	Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024	GL
05/09/24	Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024	AQ
05/09/24	Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024	GL
15/08/24	Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference	GL
01/08/24	Lumos: Q2 Earnings Snapshot	AQ
01/08/24	Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update	GL
23/07/24	Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024	GL
04/06/24	Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	AQ
04/06/24	Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	GL
20/05/24	Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024	GL
14/05/24	Lumos: Q1 Earnings Snapshot	AQ
14/05/24	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results	GL
09/05/24	Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024	GL
18/04/24	Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	GL
20/03/24	Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	GL
07/03/24	Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	GL